Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - fransk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - virus grippal réassorti (vivant atténué) de la souche suivante: a / vietnam / 1203/2004 (h5n1) - grippe humaine - vaccins - prophylaxie de la grippe dans une situation de pandémie officiellement déclarée chez les enfants et les adolescents de 12 mois à moins de 18 ans. vaccin contre la grippe pandémique h5n1 astrazeneca doit être utilisé selon les recommandations officielles.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - svensk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influensavirus (levande dämpad) av följande stam: a / vietnam / 1203/2004 (h5n1) stam - influensa, människa - vacciner - profylax av influensa i en officiellt deklarerad pandemisk situation hos barn och ungdomar från 12 månader till yngre än 18 år. pandemic influenza vaccine h5n1 astrazeneca bör användas i enlighet med officiella riktlinjer.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - spansk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - virus de la gripe reagrupado (vivo atenuado) de la siguiente cepa: cepa a / vietnam / 1203/2004 (h5n1) - influenza, humano - vacunas - profilaxis de la influenza en una situación de pandemia declarada oficialmente en niños y adolescentes de 12 meses a menos de 18 años de edad. vacuna contra la influenza pandémica h5n1 astrazeneca debe ser utilizado de acuerdo con las directrices oficiales.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - portugisisk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - vírus da gripe reassortante (vivo atenuado) da seguinte estirpe: estirpe a / vietnam / 1203/2004 (h5n1) - influenza humana - vacinas - profilaxia da gripe em uma situação de pandemia oficialmente declarada em crianças e adolescentes de 12 meses a menos de 18 anos. pandemic influenza vaccine h5n1 astrazeneca deve ser usado de acordo com orientação oficial.

Tremelimumab AstraZeneca Den europeiske union - nederlandsk - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - carcinoom, niet-kleincellige long - antineoplastische middelen - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - dansk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influenzavirus (levende svækket) af følgende stamme: a / vietnam / 1203/2004 (h5n1) stamme - influenza, human - vacciner - profylakse af influenza i en officielt erklæret pandemisk situation hos børn og unge fra 12 måneder til under 18 år. pandemic influenza vaccine h5n1 astrazeneca bør anvendes i overensstemmelse med officielle retningslinjer.

Tremelimumab AstraZeneca Den europeiske union - tysk - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - karzinom, nicht kleinzellige lunge - antineoplastische mittel - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Tremelimumab AstraZeneca Den europeiske union - dansk - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) Den europeiske union - engelsk - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant influenza virus (live attenuated) of the following strain: a/vietnam/1203/2004 (h5n1) strain - influenza, human - vaccines - prophylaxis of influenza in an officially declared pandemic situation in children and adolescents from 12 months to less than 18 years of age.pandemic influenza vaccine h5n1 astrazeneca should be used in accordance with official guidance

Tremelimumab AstraZeneca Den europeiske union - maltesisk - EMA (European Medicines Agency)

tremelimumab astrazeneca

astrazeneca ab - tremelimumab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.